Somatostatin Analogues

Abstract

The invention provides cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

1 . A method of treating somatostatin receptor expressing or accumulating tumors such as pituitary, gastro-enteropancreatic, central nervous system, breast, prostatic (including advanced hormone-refractory prostate cancer), ovarian or colonic tumours, small cell lung cancer, malignant bowel obstruction, paragangliomas, kidney cancer, skin cancer, neuroblastomas, pheochromocytomas, medullary thyroid carcinomas, myelomas, lymphomas, Hodgkins and non-Hodgkins lymphomas, bone tumours and metastases thereof, as well as autoimmune or inflammatory disorders, e.g. rheumatoid arthritis, Graves disease or other inflammatory eye diseases in a subject, wherein said method comprises administering an effective amount of a compound of formula 
       
         
           
           
               
               
           
         
         where one of the amino groups being optionally in protected form, or a salt or a complex thereof. 
       
     
     
         2 . The method according to  claim 1  wherein said somatostatin receptor expressing or accumulating tumor is a malignant bowel obstruction. 
     
     
         3 . The method according to  claim 1  wherein said somatostatin receptor expressing or accumulating tumor is a neuroendocrine tumor. 
     
     
         4 . A method of treating gastrointestinal hormone secreting tumors in a subject, wherein said method comprises administering an effective amount of a compound of formula 
       
         
           
           
               
               
           
         
         where one of the amino groups being optionally in protected form, or a salt or a complex thereof. 
       
     
     
         5 . The method according to  claim 4  wherein said gastrointestinal hormone secreting tumor is a carcinoid tumor.